GSA Capital Partners LLP Takes Position in BioMarin Pharmaceutical Inc. $BMRN

GSA Capital Partners LLP purchased a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 16,501 shares of the biotechnology company’s stock, valued at approximately $944,000.

Other hedge funds have also bought and sold shares of the company. NewEdge Advisors LLC lifted its holdings in BioMarin Pharmaceutical by 11.5% during the 1st quarter. NewEdge Advisors LLC now owns 3,769 shares of the biotechnology company’s stock worth $266,000 after buying an additional 388 shares during the last quarter. Empowered Funds LLC grew its position in shares of BioMarin Pharmaceutical by 207.4% in the 1st quarter. Empowered Funds LLC now owns 12,023 shares of the biotechnology company’s stock worth $850,000 after acquiring an additional 8,112 shares in the last quarter. Focus Partners Wealth increased its holdings in shares of BioMarin Pharmaceutical by 70.2% in the 1st quarter. Focus Partners Wealth now owns 11,817 shares of the biotechnology company’s stock valued at $835,000 after acquiring an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC increased its holdings in shares of BioMarin Pharmaceutical by 33.0% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,439 shares of the biotechnology company’s stock valued at $244,000 after acquiring an additional 1,102 shares during the last quarter. Finally, Invesco Ltd. raised its position in shares of BioMarin Pharmaceutical by 23.5% during the 2nd quarter. Invesco Ltd. now owns 618,835 shares of the biotechnology company’s stock valued at $34,017,000 after acquiring an additional 117,617 shares in the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BMRN. UBS Group restated a “neutral” rating on shares of BioMarin Pharmaceutical in a research note on Tuesday, July 14th. Sanford C. Bernstein lowered their target price on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating for the company in a research note on Tuesday, May 5th. Oppenheimer increased their target price on shares of BioMarin Pharmaceutical from $95.00 to $97.00 and gave the stock an “outperform” rating in a report on Friday, August 7th. Morgan Stanley raised their price target on shares of BioMarin Pharmaceutical from $119.00 to $124.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Finally, Barclays lifted their price target on shares of BioMarin Pharmaceutical from $105.00 to $111.00 and gave the company an “overweight” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, BioMarin Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus price target of $88.41.

BioMarin Pharmaceutical Stock Up 0.5%

Shares of BioMarin Pharmaceutical stock opened at $66.99 on Wednesday. The stock has a market capitalization of $12.97 billion, a price-to-earnings ratio of 181.05, a PEG ratio of 0.47 and a beta of 0.24. BioMarin Pharmaceutical Inc. has a twelve month low of $49.26 and a twelve month high of $70.98. The company has a current ratio of 2.39, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56. The business’s 50 day simple moving average is $59.94 and its 200-day simple moving average is $57.65.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. The business had revenue of $989.71 million during the quarter, compared to analyst estimates of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The business’s revenue for the quarter was up 20.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities research analysts forecast that BioMarin Pharmaceutical Inc. will post 4.12 earnings per share for the current year.

Key Headlines Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront, plus potential development and regulatory milestone payments. The deal gives BioMarin ALE1, a clinical-stage program that could become the first oral treatment for hypophosphatasia, a rare skeletal disease with significant unmet need. The asset could broaden BioMarin’s rare-disease pipeline and expand its exposure to larger patient markets. BioMarin to Acquire Alesta Therapeutics
• Positive Sentiment: Wedbush said the Alesta transaction strengthens BioMarin’s long-term growth outlook, reinforcing the view that ALE1 could provide a strategically attractive growth opportunity beyond the company’s existing commercial portfolio. BioMarin Pharmaceutical’s Alesta Deal Strengthens Long-Term Growth Outlook
• Positive Sentiment: Piper Sandler raised its BioMarin price target to $88 from $82 and maintained an overweight rating. Barclays also lifted its target to $111 from $105 and retained an overweight rating, reflecting substantial expected upside based on their models.
• Neutral Sentiment: HC Wainwright lowered its price target to $59 from $60 and assigned a neutral rating. The revised target implies downside from the current trading level, highlighting that some analysts view the shares as fully valued despite the pipeline opportunity.
• Neutral Sentiment: Recent coverage has also focused on BioMarin’s raised 2026 outlook and an ESOP shelf offering. The outlook may support investor confidence, while the offering introduces a potential capital-structure consideration that investors will monitor.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.